/
For nearly 45 years, NRC Health has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health s commitment to Human Understanding helps leading healthcare systems improve their operations through understanding each person they serve not as point-in-time insights, but as an ongoing relationship.
$21.68
$0.10 (-0.46%)
Live · 05:21 PM
16.44% operating margin is respectable but not wide. ROIC at 17.21%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue declined 4.0% YoY. Margins deteriorated 8.2pp alongside, both lines moving the wrong way.
Free cash flow declined 18% versus the prior year, cash generation momentum has weakened. ROIC dropped from 29.72% to 17.21%, capital efficiency is deteriorating.
0.4x earnings, 27.3x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$139M
▼ -4.0% YoY
Net Income (TTM)
$9M
▼ -54.4% YoY
Op. Margin
14.11%
▼ -8.2pp YoY
ROIC
14.75%
▼ -12.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$17M
▼ -17.9% YoY
Op. Cash Flow (TTM)
$27M
▼ -23.6% YoY
Net Debt
$75M
Cash & Equiv.
$3M
5Y CAGR: +0.6%
5Y CAGR: -15.5%
Continue Research
At a P/E of 0.4 and a price-to-free-cash-flow of 27.3, Nrc Health (NRC) trades above a two-stage DCF intrinsic value of about $10.34 per share, so at $21.68 the stock looks overvalued (52.3% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Nrc Health scores 35/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 2.5%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $10.34 per share for NRC, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $7.76. At today's $21.68, that puts the stock about 52.3% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Nrc Health scores 35 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 14.1% operating margin and a 14.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Nrc Health pays a regular dividend of about $0.54 per share per year (typically in quarterly installments), a yield of roughly 2.5% at the current price. That is a payout ratio of about 137.7% of earnings, so the dividend is stretched at this level. Nrc Health has grown the dividend at roughly 4.6% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For NRC's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. NRC currently trades above its estimated intrinsic value and scores 35/100 on quality (lower-quality). It also yields about 2.5%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.